Studies of variability in the islet amyloid polypeptide gene in relation to Type 2 diabetes

Diabetic Medicine

Volumn 20, Issue 6, 2003, Pages 491-494

  Pildal, Julie ^a   Lajer, M ^a   Hansen, S K ^a   Almind, K ^b   Ambye, L ^c   Borch Johnsen, K ^a,d   Carstensen, B ^a   Hansen, T ^a   Pedersen, O ^a  

^a STENO DIABETES CENTER   (Denmark)

^b JOSLIN DIABETES CENTER   (United States)

^c Mental Health Services CPH   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amylin; IAPP; Mutation analysis; Polymorphism; Type 2 diabetes

Indexed keywords

AMYLIN; GLUCOSE;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DENMARK; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

AMYLOID; BASE SEQUENCE; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HETERODUPLEX ANALYSIS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS);

EID: 0038798523     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00951.x     Document Type: Article

References (20)

1. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH et al. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 1990; 33: 285-289.
2. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990; 87: 5036-5040.
3. Leighton B, Cooper GJ. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632-635.
4. Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001; 50: S160-163.
5. Makimattila S, Fineman MS, Yki-Jarvinen H. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2822-2827.
6. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 1998; 47: 640-5.
7. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 97-102.
8. Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 89-96.
9. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991; 40: 1615-1619.
10. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-54.
11. Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 291-293.
12. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K et al. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 2000; 157: 2101-2109.
13. Seino S. S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. Diabetologia 2001; 44: 906-909.
14. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al. The common PPARgamma Pro12A1a polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
15. Nishi M, Bell GI, Steiner DF. Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990; 33: 628-630.
16. Hart LM, Stolk RP, Dekker JM, Nijpels G, Grobbee DE, Heine RJ et al. Prevalence of variants in candidate genes for type 2 diabetes mellitus in the Netherlands: the Rotterdam study and the Hoorn study. J Clin Endocrinol Metab 1999; 84: 1002-1006.
17. Birch CL, Fagan LJ, Armstrong MJ, Turnbull DM, Walker M. The S20G islet-associated polypeptide gene mutation in familial NIDDM (Letter). Diabetologia 1997; 40: 1113.
18. Novials A, Rojas I, Casamitjana R, Usac EF, Gomis R. A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with Type II diabetes mellitus (Letter). Diabetologia 2001; 44: 1064-1065.
19. Hansen T, Andersen CB, Echwald SM, Urhammer SA, Clausen JO, Vestergaard H et al. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997; 46: 494-501.
20. Møller AM, Jensen NM, Pildal J, Drivsholm T, Borch-Johnsen K, Urhammer SA et al. Studies of genetic variability of the glucose transporter 2 promoter in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 2181-2186.